Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
May 06, 2016 |
referred to health |
Assembly Bill A10026
2015-2016 Legislative Session
Sponsored By
MCDONALD
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
co-Sponsors
Sandy Galef
2015-A10026 (ACTIVE) - Details
2015-A10026 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 10026 I N A S S E M B L Y May 6, 2016 ___________ Introduced by M. of A. McDONALD -- read once and referred to the Commit- tee on Health AN ACT to amend the public health law, in relation to prescription drug cost transparency THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative intent. It is the intent of the legislature to make information available to the public about the cost and utilization of pharmaceutical drugs. To fulfill this goal, the legislature finds that there should be annual reporting of drug costs and use that would be of use by policymakers, government agencies and others to understand pharmacy cost trends. S 2. The public health law is amended by adding a new section 278-a to read as follows: S 278-A. PRESCRIPTION DRUG COST TRANSPARENCY. 1. EACH MANUFACTURER OF A BRAND AND GENERIC MEDICATION THAT IS MADE AVAILABLE IN NEW YORK STATE SHALL FILE A REPORT ON PHARMACEUTICAL COSTS AS OUTLINED IN THIS SECTION. 2. THE MANUFACTURER OF A PHARMACEUTICAL DRUG THAT HAS A WHOLESALE ACQUISITION COST OF ONE THOUSAND DOLLARS FOR A THIRTY DAY SUPPLY SHALL FILE A REPORT PURSUANT TO THIS SECTION ON THE COSTS FOR EACH QUALIFYING DRUG. WHOLESALE ACQUISITION COST SHALL HAVE THE SAME MEANING AS FOUND IN SUBSECTION (C) OF 42 U.S. CODE SECTION 1395W-3A. 3. THE MANUFACTURER OF A PHARMACEUTICAL DRUG WHICH DURING A THREE MONTH PERIOD HAS A CUMULATIVE PRICE INCREASE OF THREE TIMES THE CONSUMER PRICE INDEX SHALL FILE A REPORT PURSUANT TO THIS SECTION ON THE COSTS FOR EACH QUALIFYING DRUG. 4. THE REPORT SHALL INCLUDE THE FOLLOWING FOR EACH DRUG DESCRIBED IN SUBDIVISIONS TWO AND THREE OF THIS SUBDIVISION: (A) THE TOTAL COSTS FOR THE PRODUCTION OF THE DRUG INCLUDING ALL OF THE FOLLOWING: (1) THE TOTAL RESEARCH AND DEVELOPMENT COSTS INCLUDING BUT NOT LIMITED TO: EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD15199-01-6
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.